6665-78-7

Usage

Uses

Used in Pharmaceutical Industry:
5,7-Diacetoxyflavone is used as a therapeutic agent for its antioxidant and anti-inflammatory properties, which can contribute to the treatment and management of various inflammatory and oxidative stress-related conditions.
Used in Cancer Treatment:
5,7-Diacetoxyflavone is used as an anti-cancer agent, potentially aiding in the prevention and treatment of cancer by targeting various biological pathways involved in tumor growth and progression.
Used in Neuroprotection:
5,7-Diacetoxyflavone is used as a neuroprotective agent, helping to protect the nervous system from damage and degeneration, which may be beneficial in the management of neurodegenerative diseases.
Used in Cardiovascular Health:
5,7-Diacetoxyflavone is used to reduce the risk of cardiovascular diseases, potentially through its antioxidant and anti-inflammatory effects, which can help maintain healthy blood vessels and heart function.
Used in Immunomodulation:
5,7-Diacetoxyflavone is used as an immunomodulatory agent, capable of modulating the immune system's response, which may be beneficial in the treatment of autoimmune diseases and inflammatory conditions.
Used in Metabolic Health Improvement:
5,7-Diacetoxyflavone is used to improve metabolic health, potentially aiding in the regulation of glucose and lipid metabolism, which can contribute to the prevention and management of metabolic disorders such as diabetes and obesity.

Upstream product

• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 108-24-7 acetic anhydride 
• 1133835-06-9 3,5,7-trihydroxy-2-phenylchroman-4-one 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 93-97-0 benzoic acid anhydride 

Downstream Products

• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 132351-58-7 7-hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl acetate 
• 539823-65-9 acetic acid 5-hydroxy-6,8-diiodo-4-oxo-2-phenyl-4H-chromen-7-yl ester 
• 1610737-55-7 4-oxo-2-phenyl-7-(tosyloxy)-4H-chromen-5-yl acetate 
• 1610737-56-8 5-(benzyloxy)-4-oxo-2-phenyl-4H-chromen-7-yl 4-methylbenzenesulfonate 
• 1610737-57-9 5-(benzyloxy)-7-morpholino-2-phenyl-4H-chromen-4-one 
• 873302-28-4 5-hydroxy-7-(6-bromohexyloxy)-2-phenyl-4H-chromen-4-one 
• 1265223-32-2 7-oxo-1a-phenyl-7,7a-dihydro-1aH-oxireno[2,3-b]chromene-4,6-diyl diacetate 

Relevant academic research and scientific papers

Peracetylation of polyphenols under rapid and mild reaction conditions

Structural modifications are an important tool for studying the properties of naturally occurring polyphenols. Regarding the preparation of acetyl esters, the presence of hydroxyl groups stabilized by intramolecular hydrogen bonds may pose an obstacle for

Study on the synthesis, antioxidant properties, and self-assembly of carotenoid–flavonoid conjugates

Flavonoids and carotenoids possess beneficial physiological effects, such as high antioxidant capacity, anticarcinogenic, immunomodulatory, and anti-inflammatory properties, as well as protective effects against UV light. The covalent coupling of hydropho

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT

Disclosed is a pharmaceutical composition for preventing or treating diabetes complications containing a novel chrysin derivative compound as an active ingredient, and more specifically, a pharmaceutical composition for preventing or treating diabetes complications containing, as an active ingredient, a novel chrysin derivative compound that is capable of preventing or treating diabetes complications due to the ability thereof to inhibit the formation of an advanced glycation end-product (AGE).

Anti-glycation, carbonyl trapping and anti-inflammatory activities of chrysin derivatives

The aim of this study was searching anti-glycation, carbonyl trapping and anti-inflammatory activities of chrysin derivatives. The inhibitory effect of chrysin on advanced glycation end-products (AGEs) was investigated by trapping methylglyoxal (MGO), and MGO-conjugated adducts of chrysin were analyzed using LC-MS/MS. The mono- or di-MGO-conjugated adducts of chrysin were present at 63.86 and 29.69% upon 48 h of incubation at a chrysin:MGO ratio of 1:10. The MGO adducted positions on chrysin were at carbon 6 or 6 & 8 in the A ring by classic aldol condensation. To provide applicable knowledge for developing chrysin derivatives as AGE inhibitors, we synthesized several O-alkyl or ester derivatives of chrysin and compared their AGE formation inhibitory, anti-inflammatory, and water solubility characteristics. The results showed that 5,7-di-O-acetylchrysin possessed higher AGE inhibitory and water solubility qualities than original chrysin, and retained the anti-inflammation activity. These results suggested that 5,7-di-O-acetylchrysin could be a potent functional food ingredient as an AGE inhibitor and anti-inflammatory agent, and promotes the development of the use of chrysin in functional foods.

Fluorination of flavones and chromones using elemental fluorine

Flavonoids are abundant micronutrients in our diet, possessing various biological activities. Fluorine was successfully added across the double bond of various flavones and chromones. The difluoro derivative products were easily dehydrofluorinated to form

Synthesis and antitumor activity evaluation of chrysin derivatives

A series of 5,7-disubstituted chrysin, 7-monosubstituted chrysin, 5-monosubstituted chrysin derivatives were synthesized by alkylation, acetylation, benzoylation, carboxymethylation, and evaluated on their antitumor activity of H22 cells in the search for potential antitumor agents. Among them, compound 3 (5,7-diacetyl chrysin) displayed the most potent antitumor activity with IC50 value of 141 μM. Moreover, there is significant up-regulation of G2 in cell cycle of H22.

Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75

HIV integrase (IN) is an essential enzyme for the viral replication. Currently, three IN inhibitors have been approved for treating HIV-1 infection. All three drugs selectively inhibit the strand transfer reaction by chelating a divalent metal ion in the

APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF

In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).

Synthesis and anticancer effect of chrysin derivatives

A series of chrysin derivatives, prepared by alkylation, halogenation, nitration, methylation, acetylation and trifluoromethylation, were tested in vitro against human gastric adenocarcinoma cell line (SGC-7901) and colorectal adenocarcinoma (HT-29) cells. Among these derivatives of chrysin, 5,7-dimethoxy-8-iodochrysin 3 and 8-bromo-5-hydroxy-7-methoxychrysin 11 have the strongest activities against SGC-7901 and HT-29 cells, respectively. 5,7-Dihydroxy-8-nitrochrysin 12 were found to have strong activities against both SGC-7901 and HT-29 cells.

Synthesis and hypoglycemic effect of chrysin derivatives

A series of 18 chrysin derivatives, prepared by alkylation and condensation, were fully characterized by NMR and other techniques and tested in vivo against the diabetes mellitus. Several modified compounds especially those with propyl, butyl, octyl and tolyl groups were found to have hypoglycemic effect on diabetic mice in spite of the fact that chrysin itself had inhibited insulin release by 40-60%. None of the test animals died at the maximum dose 500mg/kg and did not cause any significant change in general feature, water and food consumption, body weight and organ weight when we examined the acute oral toxicity of those compounds having significant hypoglycemic effect.